Tirzepatide · 3 min read
A month-by-month walk up the ladder: what happens clinically at 2.5, 5, 7.5, and 10 mg, and what each month bills on flat versus dose-scaled versus brand pricing.
A month-by-month walk up the ladder: what happens clinically at 2.5, 5, 7.5, and 10 mg, and what each month bills on flat versus dose-scaled versus brand pricing.
Titration is where tirzepatide's clinical design and its pricing design intersect, so this guide walks the ladder both ways at once: what each phase does in your body, and what it does on your card.
The starter dose exists for tolerability, not efficacy; appetite effects are usually modest and GI side effects are introducing themselves. Clinically: eat smaller, slower, and do not judge the drug yet. Financially, this is the month the market prices to advertise: Fifty 410's $133, ShedRx's $199, IVIM's $208 entry, and Zepbound's famous $299 vial all describe this rung. Flat programs (NexLife $215, SkinnyRx $299) charge here what they will charge forever.
The 5 mg step is where most people first feel the full effect — meaningful appetite suppression, early scale movement, and in SURMOUNT-1 a dose that averaged 15.0% loss over 72 weeks on its own. Nausea risk peaks in the week or two after the step; the standard management is the side-effects playbook, and the standard mistake is escalating on schedule despite symptoms. Financially, Zepbound steps to $399; scaled compounded programs step to their middle tiers; flat programs do not move.
Increases beyond 5 mg are optional, response-driven, and spaced at least four weeks. Many patients settle at 10 mg — our ranking basis — and some hold 7.5 mg or continue to 12.5–15 mg over subsequent months. The clinical logic: the lowest dose that sustains the response, since side effects and (on scaled plans) cost climb with each rung while marginal benefit varies. Financially this is where the ladders diverge for good: Zepbound reaches its $449 plateau at 7.5 mg; ShedRx reaches ~$289, IVIM ~$278 all-in, Lavender Sky ~$352; NexLife is still $215, and every flat-rate program still costs its month-one price.
A standard 2.5→5→7.5→10 titration costs about $860 on NexLife (four flat months), roughly $1,000–$1,100 on the scaled mid-market, and $1,596 on Zepbound via LillyDirect ($299 + $399 + $449 + $449). Stretch any step by an extra month — common, and clinically sound when symptoms say so — and flat pricing's advantage compounds. Price your ladder before you climb it: the maintenance-cost guide and pricing database carry every program's full-ladder math.
Titration pacing is individual and belongs to you and your prescriber; the four-week minimum between increases is a floor, not a schedule.
The minimum path from 2.5 mg to a 10 mg maintenance dose is about four months (four-week steps); to 15 mg, about six. Many patients take longer by design, holding doses that are working or pausing escalation for tolerability.
Yes — 5 mg is a legitimate maintenance dose that averaged 15.0% weight loss in SURMOUNT-1. Escalation beyond 5 mg is optional and response-driven.
The standard four-month climb to 10 mg runs about $860 on the cheapest flat compounded program (NexLife), $1,000–$1,100 mid-market, and $1,596 on brand Zepbound via LillyDirect.